Sanofi Appoints Belen Garijo as New CEO, Replaces Paul Hudson

Sanofi has announced the departure of Paul Hudson as its Chief Executive Officer, effective immediately. The decision comes as the company faces challenges in its clinical pipeline, prompting the board to seek new leadership. Belen Garijo, currently the CEO of Merck KGaA, has been appointed as Hudson’s successor and will officially take on the role on April 29, 2024.

Hudson, who assumed leadership at Sanofi in 2019, focused on enhancing the company’s research and development efforts. Under his guidance, Sanofi aimed to strengthen its portfolio, particularly in immunology, in anticipation of the impending expiration of patent protections for its flagship product, Dupixent. This immunotherapy, developed in collaboration with Regeneron Pharmaceuticals, has generated significant revenue for the company and is projected to remain a key player until patent protections end in the early 2030s.

Despite Hudson’s strategic vision, which included increased investment in research programs, the company has faced recent clinical setbacks that have raised concerns among investors. His approach, while aimed at positioning Sanofi as a leader in immunology research, sometimes led to uncertainty regarding the company’s short-term financial performance.

In her new role, Garijo will inherit the challenge of revitalizing Sanofi’s pipeline while addressing investor concerns. Her experience at Merck KGaA, where she has led initiatives in biopharmaceuticals and digital health, positions her to bring a fresh perspective to Sanofi’s strategic direction.

The transition in leadership marks a significant moment for Sanofi, as it seeks to navigate a competitive landscape in the pharmaceutical industry. Garijo’s appointment is expected to signal a shift in strategy, potentially prioritizing immediate revenue generation alongside long-term research investments.

As Sanofi prepares for this leadership change, stakeholders will be closely monitoring how Garijo’s vision will align with the company’s goals in the coming years. With the pharmaceutical market evolving rapidly, her ability to balance innovation with financial performance will be crucial for the company’s future success.